港股异动|洛阳钼业涨逾3%获GICPrivate增持525万股
格隆汇7月19日丨洛阳钼业(3993.HK)现报2.41港元,涨3.43%,暂成交2334万港元,最新总市值520.5亿港元。根据港交所最新权益资料显示,洛阳钼业获GICPrivate于7月11日在场內以每股均价2.3067港元增持525万股,涉资约1211.02万港元。增持后,GICPrivateLimited的持股数目为275,631,000股,最新持股比例由6.87%升至7.01%。此前上周二(9日)曾公布,子公司CMOC斥资4.7亿美元购买NSRC100%股权间接收购IXM项目,近日已收到通知,本次收购项目获得俄罗斯联邦竞争管理局反垄断批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.